Projected Price to Earnings: Neumora Therapeutics Inc (NMRA)

Graphic logo of Neumora Corp (NMRA)

Neumora Therapeutics (NMRA) is developing partnerships with biopharma behemoths to create personalized anxiety and depression treatments using big data analysis. The immediate growth driver will be the results of Phase II trials for its primary antidepressant, while previous R&D challenges are already priced in. This chart illustrates the asset's value with a Forward P/E of 0.00, visualizing the market valuation of this neuromedicine developer.

Projected Price to Earnings: Neumora Therapeutics, Inc. (NMRA) for 02/21/2024 - 11/17/2026

Financial and market metric breakdowns for Neumora Therapeutics (NMRA)

- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:Neumora Therapeutics Inc NMRA
Signature product of Neumora Corp

The forward P/E reflects the dependence of Neumora Therapeutics (NMRA) market value on expected net income based on financial reporting. This indicator compares current capitalization with projected earnings to test the asset's valuation resilience against volatility. This is critical for the biotech sector, as low mass-production costs following drug patenting ensure a sharp increase in margins. By analyzing the forward P/E chart for Neumora Therapeutics (NMRA), an investor can distinguish fundamental growth from speculative spikes.

Direct competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Neurogene Inc. - Price to Future Earnings Ratio|acimmune.com - Projected Price to Earnings|Forward P/E Multiple Voyager Therapeutics Inc VYGR|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)